Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer
نویسندگان
چکیده
Testing for HER2/neu in breast cancer at the time of primary diagnosis is now the standard of care. Accurate and standardized testing methods are of prime importance to ensure the proper classification of the patient's HER2/neu status. A meeting of pathologists from across Canada was convened to update the Canadian HER2/neu testing guidelines. This National HER2/neu Testing Committee reviewed the recently published American Society of Clinical Oncology/ College of American Pathologists (ASCO/CAP) guidelines for HER2/neu testing in breast cancer. The updated Canadian HER2/neu testing guidelines are based primarily on the ASCO/CAP guidelines, with some modifications. It is anticipated that widespread adoption of these guidelines will further improve the accuracy of HER2/neu testing in Canada.
منابع مشابه
HER2 testing in breast cancer: NCCN Task Force report and recommendations.
The NCCN HER2 Testing in Breast Cancer Task Force was convened to critically evaluate the ability of the level of HER2 expression or gene amplification in breast cancer tumors to serve as a prognostic and a predictive factor in the metastatic and adjuvant settings, to assess the reliability of the methods of measuring HER2 expression or gene amplification in the laboratory, and to make recommen...
متن کاملتفسیر نتایج ایمنوهیستوشیمی بیان HER2/neu در سرطان مهاجم پستان: بررسی توافق بین مشاهدهکنندگان و در دو بار مشاهده توسط یک نفر
Background and Aim: The accurate determination of HER-2 in invasive breast cancer has become a critical issue, particularly in context of the results of Herceptin adjuvant therapy. The aim of this study was to evaluate inter- and intraobserver reproducibility of assessment of HER2/neu immunostaining in invasive breast cancerMaterials and Methods: This study was cross sectional and the conve...
متن کاملبررسی هیستوپاتولوژی و مارکرهای بیولوژی در زنان مبتلا به سرطان پستان قبل از یائسگی (زیر 40 سال) و پس از یائسگی (بالای 60 سال) در بیمارستان رسول اکرم(ص) و آتیه
Background & Aim: Breast carcinoma is the most common malignant tumor and the leading cause of carcinoma death in women.One of the factors which have been proposed in prognosis and treatment of breast carcinoma is hormonal status and hormonal receptors. In this study, we investigated histopathology(prognostic factors) and biologic markers(estrogen receptor ER, progesterone receptor PR, P53...
متن کاملOptimization of a Method to Prepare Liposomes Containing HER2/Neu-Derived Peptide as a Vaccine Delivery System for Breast Cancer
The purpose of this study was to optimize a method for the encapsulation of P5 peptide, a new designed peptide containing MHC class I epitopes from rat HER2/neu protein, into liposomes as an approach for breast cancer vaccine formulation. The efficiency of liposomal encapsulation of peptides is generally low and development of an optimized method to increase encapsulation efficiency is a big ch...
متن کاملImaging features of estrogen-negative breast cancers: a correlation study with human epidermal growth factor type II overexpression
Background: Estrogen-negative breast cancers have different clinical course, prognostic features and treatment response in comparison to estrogen receptor-positive (ER-positive) breast cancers. Human epidermal growth factor receptor 2 (HER2) oncoprotein has found to have a pivotal role in natural cell growth and cell division and is suggested to be directly related to tumor invasiveness in brea...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Current Oncology
دوره 14 شماره
صفحات -
تاریخ انتشار 2007